Abstract Number: 1521 • 2013 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area
Background/Purpose: Anti-TNF agents have emerged as an important treatment for rheumatic diseases, particularly for ankylosing spondylitis (AS). Screening and treatment of latent tuberculosis infection (LTBI)…Abstract Number: 1522 • 2013 ACR/ARHP Annual Meeting
Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study
Background/Purpose: Remission is the current target of management of chronic rheumatic diseases. Whereas in rheumatoid arthritis remission criteria have been recently proposed, in spondyloarthritis, no…Abstract Number: 1523 • 2013 ACR/ARHP Annual Meeting
Presence Of Peripheral Arthritis Delays Spinal Radiographic Progression In Ankylosing Spondylitis: Observation Study Of Korean Spondyloarthropathy Registry (OSKAR) Over 5 Years
Background/Purpose: The most unique feature in ankylosing spondylitis (AS) is subchondral eburnation and syndesmophytes, possibly leading to ankylosis and spinal fusion. So far a clear…Abstract Number: 1525 • 2013 ACR/ARHP Annual Meeting
Measurement Of Lateral Spinal Flexion and Schober Is Sufficient To Be Informed About Spinal Mobility In Patients With Ankylosing Spondylitis: 12-Year OASIS Results
Background/Purpose: We have shown that spinal mobility gets impaired in a fixed order in ankylosing spondylitis (AS), with the highest impairment in lumbar spine. We…Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting
Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial
Background/Purpose: < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…Abstract Number: 1527 • 2013 ACR/ARHP Annual Meeting
Routine Assessment Of Patient Index Data 3 Scores Correlate Well With Bath Ankylosing Spondylitis Disease Activity Index In The Assessment Of Disease Activity and Monitoring Progression Of Ankylosing Spondylitis
Background/Purpose: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a composite tool unique to measure disease activity in ankylosing spondylitis (AS) just as Disease Activity…Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting
Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Background/Purpose: Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…Abstract Number: 1529 • 2013 ACR/ARHP Annual Meeting
Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Background/Purpose: Efficacy of TNF alpha inhibitors (TNFi) has been clearly established in patients with axial SpondyloArthritis (ax-SpA), but its effectiveness and adherence with regard to…Abstract Number: 1530 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Associated With a More Active and Severe Disease In Early Axial Spondyloarthritis: Data From The DESIR Cohort
Background/Purpose: Objectives a) to describe the vitamin D status b) to assess the relationship between vitamin D status and disease activity/severity and c) to estimate…Abstract Number: 1531 • 2013 ACR/ARHP Annual Meeting
Agreement Between Disease Activity States and Improvement Scores As Defined by Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score Cut-Off Values
Background/Purpose: BASDAI has been extensively used to assess disease activity in ankylosing spondylitis (AS) BASDAI score ≥4 represent high disease activity and has been suggested as…Abstract Number: 1532 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis
Background/Purpose: Radiography of the sacroiliac joints (SIJ) in spondyloarthritis (SpA) is a valuable diagnostic tool but is unreliable and unresponsive for assessment of treatment effects.…Abstract Number: 1533 • 2013 ACR/ARHP Annual Meeting
Work Outcome In Patients With Ankylosing Spondylitis: 12-Year Results From OASIS
Background/Purpose: Almost all studies on the impact of Ankylosing Spondylitis (AS) on the employment status or work disability (WD), the far majority of these studies…Abstract Number: 1534 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody Injected Subcutaneously Every 4 Weeks, In Chinese Patients With Active Ankylosing Spondylitis: 1-Year Results Of a Phase 3, Randomized, Placebo-Controlled Study
Background/Purpose: A multicenter, randomized, placebo (PBO)-controlled study of golimumab (GLM) was performed in Chinese pts with ankylosing spondylitis (AS). To assess efficacy and safety of…Abstract Number: 1535 • 2013 ACR/ARHP Annual Meeting
Phenotype Of Patients and Impact Of The Disease In Early Spondyloarthritis Are Similar Regardless The Arm Of The Assessment In Spondyloarthritis International Society Criteria (“imaging” or “clinical”) Fulfilled By The Patients. Data From The DESIR Cohort
Background/Purpose: Patients can fulfil the ASAS (Assessment of SpondyloArthritiS) sets of criteria with either objective evidence of sacroiliac joint damage (X-Ray) or inflammation (MRI): (“imaging”…Abstract Number: 1536 • 2013 ACR/ARHP Annual Meeting
Do Patients With Ankylosing Spondylitis Have An Excess Prevalence Of Chronic Widespread PAIN?: Results From The Scotland and Ireland Registry For Ankylosing Spondylitis (SIRAS) and The Musician Study
Background/Purpose: To determine whether there is an excess prevalence of chronic widespread body pain (CWP) in patients with Ankylosing spondylitis (AS). Methods: Patients were…